

# MERILOG- insulin aspart-szjj injection, solution

## Sanofi-Aventis U.S. LLC

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MERILOG safely and effectively. See full prescribing information for MERILOG™.

**MERILOG (insulin aspart-szjj) injection, for subcutaneous use.**

**Initial U.S. Approval: 2025**

**MERILOG™ (insulin aspart-szjj) is biosimilar\* to NOVOLOG® (insulin aspart).**

### INDICATIONS AND USAGE

MERILOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus (1).

### DOSAGE AND ADMINISTRATION

See Full Prescribing Information for important preparation, administration, and dosage instructions (2.1, 2.2, 2.3, 2.4, 2.5).

- *Subcutaneous injection (2.2):*
  - Inject subcutaneously within 5–10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
  - Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
  - Should generally be used in regimens with an intermediate- or long-acting insulin.
- Individualize and adjust the dosage of MERILOG based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal (2.3).
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness (2.3).

### DOSAGE FORMS AND STRENGTHS

Injection: 100 units/mL (U-100) of insulin aspart-szjj available as: (3)

- 10 mL multiple-dose vial
- 3 mL single-patient-use MERILOG SoloStar® prefilled pen

### CONTRAINDICATIONS

- During episodes of hypoglycemia (4).
- Hypersensitivity to insulin aspart products or any of the excipients in MERILOG.(4).

### WARNINGS AND PRECAUTIONS

- *Never share* a MERILOG SoloStar prefilled pen between patients, even if the needle is changed (5.1).
- *Hyperglycemia or hypoglycemia with changes in insulin regimen:* Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring (5.2).
- *Hypoglycemia:* May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness (5.3).
- *Medication Errors:* Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection (5.4).
- *Hypersensitivity reactions:* Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. Discontinue MERILOG, treat, and monitor, if indicated (5.5).
- *Hypokalemia:* May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated (5.6).
- *Fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs):* Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs (5.7).

### ADVERSE REACTIONS

Adverse reactions observed with insulin aspart products include: hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus (6).

To report **SUSPECTED ADVERSE REACTIONS**, contact sanofi-aventis at **1-800-633-1610** or **FDA at 1-800-FDA-1088** or **www.fda.gov/medwatch**.

-----  
**DRUG INTERACTIONS**  
-----

- *Drugs that may increase the risk of hypoglycemia:* Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics (7).
- *Drugs that may decrease the blood glucose lowering effect:* Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones (7).
- *Drugs that may increase or decrease the blood glucose lowering effect:* Alcohol, beta-blockers, clonidine, lithium salts, and pentamidine (7).
- *Drugs that may blunt the signs and symptoms of hypoglycemia:* Beta-blockers, clonidine, guanethidine, and reserpine (7).

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

\* Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of MERILOG has been demonstrated for the condition(s) of use (e.g., indication (s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

**Revised: 2/2025**

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

**2 DOSAGE AND ADMINISTRATION**

2.1 Important Preparation and Administration Instructions

2.2 Preparation and Administration Instructions for the Approved Routes of Administration

2.3 Dosage Recommendations

2.4 Dosage Modifications for Drug Interactions

2.5 Instructions for Mixing MERILOG with Other Insulins

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

5.1 Never Share a MERILOG SoloStar Prefilled Pen Between Patients

5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

5.3 Hypoglycemia

5.4 Hypoglycemia Due to Medication Errors

5.5 Hypersensitivity Reactions

5.6 Hypokalemia

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists

**6 ADVERSE REACTIONS**

6.1 Clinical Trials Experience

6.2 Immunogenicity

6.3 Postmarketing Experience

**7 DRUG INTERACTIONS**

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

## **10 OVERDOSAGE**

## **11 DESCRIPTION**

## **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

## **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

## **14 CLINICAL STUDIES**

- 14.1 Overview of Clinical Studies
- 14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections
- 14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Recommended Storage

## **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

MERILOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Important Preparation and Administration Instructions**

- Always check insulin labels before administration [*see Warnings and Precautions (5.4)*].
- Inspect MERILOG visually before use. It should appear clear and colorless. Do not use MERILOG if particulate matter or coloration is seen.
- Use MERILOG SoloStar prefilled pen with caution in patients with visual impairment who may rely on audible clicks to dial their dose.

#### **2.2 Preparation and Administration Instructions for the Approved Routes of Administration**

## Subcutaneous Injection

- Inject MERILOG subcutaneously within 5–10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
- Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see *Warnings and Precautions (5.2) and Adverse Reactions (6.1, 6.3)*].
- The MERILOG SoloStar prefilled pen dials in 1-unit increments.
- Generally use MERILOG (administered by subcutaneous injection) in regimens with an intermediate- or long-acting insulin.

## **2.3 Dosage Recommendations**

- Individualize the dosage of MERILOG based on the patient's metabolic needs, blood glucose monitoring results and glycemic control goal.
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see *Warnings and Precautions (5.2, 5.3) and Use in Specific Populations (8.6, 8.7)*].
- When switching from another insulin to MERILOG, a different dosage of MERILOG may be needed [see *Warnings and Precautions (5.2)*].
- During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see *Warnings and Precautions (5.2)*].

## **2.4 Dosage Modifications for Drug Interactions**

- Dosage modification may be needed when MERILOG is used concomitantly with certain drugs [see *Drug Interactions (7)*].

## **2.5 Instructions for Mixing MERILOG with Other Insulins**

Do **not** mix MERILOG with any other insulin.

## **3 DOSAGE FORMS AND STRENGTHS**

Injection: 100 units/mL (U-100) is a clear and colorless solution available as:

- 10 mL multiple-dose vial
- 3 mL single-patient-use MERILOG SoloStar<sup>®</sup> prefilled pen

## **4 CONTRAINDICATIONS**

MERILOG is contraindicated:

- During episodes of hypoglycemia [see *Warnings and Precautions (5.3)*].
- In patients with hypersensitivity to insulin aspart products or any of the excipients in MERILOG [see *Warnings and Precautions (5.5)*].

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Never Share a MERILOG SoloStar Prefilled Pen Between Patients**

MERILOG SoloStar prefilled pen should never be shared between patients, even if the

needle is changed. Patients using MERILOG vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

## **5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen**

Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see *Warnings and Precautions (5.3)*] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see *Adverse Reactions (6.1, 6.3)*].

Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

## **5.3 Hypoglycemia**

Hypoglycemia is the most common adverse reaction of all insulins, including insulin aspart products. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).

Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see *Drug Interactions (7)*], or in patients who experience recurrent hypoglycemia.

### Risk Factors for Hypoglycemia

The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of insulin aspart products may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see *Clinical Pharmacology (12.2)*]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to concomitantly administered medication [see *Drug Interactions (7)*]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see *Use in Specific Populations (8.6, 8.7)*].

### Risk Mitigation Strategies for Hypoglycemia

Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of

hypoglycemia; increased frequency of blood glucose monitoring is recommended. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.

#### **5.4 Hypoglycemia Due to Medication Errors**

Accidental mix-ups between insulin products have been reported. To avoid medication errors between MERILOG and other insulins, instruct patients to always check the insulin label before each injection.

#### **5.5 Hypersensitivity Reactions**

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including insulin aspart products. If hypersensitivity reactions occur, discontinue MERILOG; treat per standard of care and monitor until symptoms and signs resolve [see *Adverse Reactions (6)*]. MERILOG is contraindicated in patients who have had hypersensitivity reactions to insulin aspart products or any of the excipients in MERILOG [see *Contraindications (4)*].

#### **5.6 Hypokalemia**

All insulins, including insulin aspart products, can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentration).

#### **5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists**

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including MERILOG, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

### **6 ADVERSE REACTIONS**

The following adverse reactions are also discussed elsewhere:

- Hypoglycemia [see *Warnings and Precautions (5.3)*]
- Hypoglycemia Due to Medication Errors [see *Warnings and Precautions (5.4)*]
- Hypersensitivity Reactions [see *Warnings and Precautions (5.5)*]
- Hypokalemia [see *Warnings and Precautions (5.6)*]

#### **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in

another clinical trial, and may not reflect the rates actually observed in clinical practice. The safety of insulin aspart was evaluated in two treat-to-target trials of 6 months duration, conducted in patients with type 1 diabetes or type 2 diabetes [see *Clinical Studies (14)*].

The data in Table 1 reflect the exposure of 596 patients with type 1 diabetes to insulin aspart in one clinical trial with a mean exposure duration to insulin aspart of 24 weeks. The mean age was 39 years. Fifty-one percent were male, 94% were Caucasian, 2% were Black and 4% were other races. The mean body mass index (BMI) was 25.6 kg/m<sup>2</sup>. The mean duration of diabetes was 15.7 years and the mean HbA<sub>1c</sub> at baseline was 7.9%.

The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to insulin aspart in one clinical trial with a mean exposure duration to insulin aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 76% were Caucasian, 9% were Black and 15% were other races. The mean BMI was 29.7 kg/m<sup>2</sup>. The mean duration of diabetes was 12.7 years and the mean HbA<sub>1c</sub> at baseline was 8.1%.

Common adverse reactions were defined as events that occurred in ≥5%, excluding hypoglycemia, of the population studied. Common adverse events that occurred at the same rate or greater for insulin aspart-treated patients than in comparator-treated patients during clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus (other than hypoglycemia) are listed in Table 1 and Table 2, respectively.

**Table 1: Adverse reactions that occurred in ≥5% of Type 1 Diabetes Mellitus Adult Patients treated with insulin aspart and at the same rate or greater on insulin aspart than on comparator**

	<b>Insulin aspart + NPH (%) (n= 596)</b>	<b>Regular Human Insulin + NPH (%) (n= 286)</b>
Headache	12	10
Injury accidental	11	10
Nausea	7	5
Diarrhea	5	3

**Table 2: Adverse reactions that occurred in ≥5% of Type 2 Diabetes Mellitus Adult Patients treated with insulin aspart and at the same rate or greater on insulin aspart than on comparator**

	<b>Insulin aspart + NPH (%) (n= 91)</b>	<b>Human Regular Insulin + NPH (%) (n= 91)</b>
Hyporeflexia	11	7
Onychomycosis	10	5
Sensory disturbance	9	7
Urinary tract infection	8	7

Chest pain	5	3
Headache	5	3
Skin disorder	5	2
Abdominal pain	5	1
Sinusitis	5	1

### Severe Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including insulin aspart products [see *Warnings and Precautions (5.3)*]. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for insulin aspart with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice.

Severe hypoglycemia was defined as hypoglycemia associated with central nervous system symptoms and requiring the intervention of another person or hospitalization. The incidence of severe hypoglycemia in:

- Adult and pediatric patients with type 1 diabetes mellitus who received subcutaneous insulin aspart was 17% at 24 weeks and 6% at 24 weeks, respectively [see *Clinical Studies (14)*].
- Adult patients with type 2 diabetes mellitus who received subcutaneous insulin aspart was 10% at 24 weeks.

### Allergic Reactions

Some patients taking insulin, including insulin aspart products have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported.

### Adverse Reactions Associated with Insulin Initiation and Glucose Control Intensification

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

### Lipodystrophy

Administration of insulin, including insulin aspart products subcutaneously, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients [see *Dosage and Administration (2.2)*].

### Peripheral Edema

Insulins, including insulin aspart products, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

### Weight Gain

Weight gain has occurred with insulins, including insulin aspart products, and has been



attributed to the anabolic effects of insulin and the decrease in glucosuria.

## 6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other insulin aspart products may be misleading.

In a 6-month study with a 6-month extension in adult subjects with type 1 diabetes, 99.8% of patients who received insulin aspart were positive for anti-insulin antibodies (AIA) at least once during the study, including 97.2% that were positive at baseline. A total of 92.1% of patients who received insulin aspart were positive for anti-drug antibodies (ADA) at least once during the study, including 64.6% that were positive at baseline.

In a phase 3 type 1 diabetes clinical trial of insulin aspart, initial increase in titers of antibodies to insulin, followed by a decrease to baseline values, was observed in regular human insulin and insulin aspart treatment groups with similar incidences. These antibodies did not cause deterioration in glycemic control or necessitate increases in insulin dose.

## 6.3 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of insulin aspart products. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Medication errors have been reported in which other insulins have been accidentally substituted for insulin aspart products.

Localized cutaneous amyloidosis at the injection site has occurred with insulin aspart products. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.

## 7 DRUG INTERACTIONS

The table below presents clinically significant drug interactions with MERILOG.

<b>Drugs That May Increase the Risk of Hypoglycemia</b>	
<i>Drugs:</i>	Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when MERILOG is concomitantly administered with these

	drugs.
<b>Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG</b>	
<i>Drugs:</i>	Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when MERILOG is concomitantly administered with these drugs.
<b>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of MERILOG</b>	
<i>Drugs:</i>	Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when MERILOG is concomitantly administered with these drugs.
<b>Drugs That May Blunt Signs and Symptoms of Hypoglycemia</b>	
<i>Drugs:</i>	Beta-blockers, clonidine, guanethidine and reserpine
<i>Intervention:</i>	Increased frequency of glucose monitoring may be required when MERILOG is concomitantly administered with these drugs.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Available information from published randomized controlled trials with insulin aspart products use during the second trimester of pregnancy have not reported an association with insulin aspart products and major birth defects or adverse maternal or fetal outcomes [see *Data*]. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see *Clinical Considerations*].

In animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures 8-times and equal to the human subcutaneous dose of 1 unit/kg/day, respectively. Pre- and post-implantation losses and visceral/skeletal abnormalities were seen at higher exposures, which are considered secondary to maternal hypoglycemia. These effects were similar to those observed in rats administered regular human insulin [see *Data*].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a periconceptual HbA<sub>1c</sub> >7% and has been reported to be as high as 20 to 25% in women with a periconceptual HbA<sub>1c</sub> >10%. The estimated

background risk of miscarriage for the indicated population is unknown.

## Clinical Considerations

### *Disease-Associated Maternal and/or Embryo-Fetal Risk*

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

## Data

### *Human Data*

Published data from 5 randomized controlled trials of 441 pregnant women with diabetes mellitus treated with insulin aspart products during the late 2<sup>nd</sup> trimester of pregnancy did not identify an association of insulin aspart products with major birth defects or adverse maternal or fetal outcomes. However, these studies cannot definitely establish the absence of any risk because of methodological limitations, including a variable duration of treatment and small size of the majority of the trials.

### *Animal Data*

Fertility, embryo-fetal and pre- and postnatal development studies have been performed with insulin aspart and regular human insulin in rats and rabbits. In a combined fertility and embryo-fetal development study in rats, insulin aspart was administered before mating, during mating, and throughout pregnancy. Further, in a pre- and postnatal development study insulin aspart was given throughout pregnancy and during lactation to rats. In an embryo-fetal development study insulin aspart was given to female rabbits during organogenesis. The effects of insulin aspart did not differ from those observed with subcutaneous regular human insulin. Insulin aspart, like human insulin, caused pre- and post-implantation losses and visceral/skeletal abnormalities in rats at a dose of 200 units/kg/day (approximately 32 times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents) and in rabbits at a dose of 10 units/kg/day (approximately three times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents). No significant effects were observed in rats at a dose of 50 units/kg/day and in rabbits at a dose of 3 units/kg/day. These doses are approximately 8 times the human subcutaneous dose of 1 unit/kg/day for rats and equal to the human subcutaneous dose of 1 unit/kg/day for rabbits, based on human exposure equivalents. The effects are considered secondary to maternal hypoglycemia.

## **8.2 Lactation**

### Risk Summary

There are no data on the presence of insulin aspart products in human milk, the effects on the breastfed infant, or the effect on milk production. One small published study reported that exogenous insulin, including insulin aspart, was present in human milk. However, there is insufficient information to determine the effects of insulin aspart products on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MERILOG, and any potential adverse effects on the breastfed infant from MERILOG, or from the underlying maternal condition.

## 8.4 Pediatric Use

The safety and effectiveness of MERILOG to improve glycemic control have been established in pediatric patients with diabetes mellitus. Use of MERILOG for this indication is supported by evidence from an adequate and well-controlled study of insulin aspart in 283 pediatric patients with type 1 diabetes mellitus aged 6 to 18 years and from studies in adults with diabetes mellitus [see *Adverse Reactions (6.1)*, *Clinical Pharmacology (12.3)*, and *Clinical Studies (14)*].

## 8.5 Geriatric Use

Of the total number of patients (n=1,375) treated with insulin aspart in 3 controlled clinical studies, 2.6% (n=36) were 65 years of age or over. One-half of these patients had type 1 diabetes (18/1285) and the other half had type 2 diabetes (18/90). The HbA<sub>1c</sub> response to insulin aspart, as compared to regular human insulin, did not differ by age.

## 8.6 Renal Impairment

Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent MERILOG dose adjustment and more frequent blood glucose monitoring [see *Warnings and Precautions (5.3)* and *Clinical Pharmacology (12.3)*].

## 8.7 Hepatic Impairment

Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent MERILOG dose adjustment and more frequent blood glucose monitoring [see *Warnings and Precautions (5.3)* and *Clinical Pharmacology (12.3)*].

## 10 OVERDOSAGE

Excess insulin administration may cause hypoglycemia and hypokalemia [see *Warnings and Precautions (5.3, 5.6)*]. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

## 11 DESCRIPTION

Insulin aspart-szjj is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing *Escherichia coli*. Insulin aspart-szjj has a molecular weight of 5825.8 Da.

MERILOG (insulin aspart-szjj) injection is a sterile, clear, and colorless solution for subcutaneous use. Each mL contains 100 units of insulin aspart-szjj and the inactive ingredients: 1.72 mg metacresol, 1.50 mg phenol, 0.02 mg polysorbate 20, 6.80 mg sodium chloride, 0.04 mg zinc chloride and Water for Injection, USP. MERILOG has a pH of 7.0–7.8. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH.

## 12 CLINICAL PHARMACOLOGY


### 12.1 Mechanism of Action

The primary activity of insulin, including insulin aspart products is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

### 12.2 Pharmacodynamics

#### Pharmacodynamics of Insulin Aspart After Subcutaneous Administration

The pharmacodynamic profile of insulin aspart given subcutaneously in 22 patients with type 1 diabetes is shown in Figure 1. The maximum glucose-lowering effect of insulin aspart occurred between 1 and 3 hours after subcutaneous injection (0.15 units/kg). The duration of action for insulin aspart is 3 to 5 hours. The time course of action of insulin and insulin analogs such as insulin aspart products may vary considerably in different individuals or within the same individual. The parameters of insulin aspart activity (time of onset, peak time and duration) as designated in Figure 1 should be considered only as general guidelines. The rate of insulin absorption and onset of activity is affected by the site of injection, exercise, and other variables [see *Warnings and Precautions* (5.3)].



**Figure 1. Serial mean serum glucose collected up to 6 hours following a single 0.15 units/kg pre-meal dose of insulin aspart (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 diabetes.**

### 12.3 Pharmacokinetics

Pharmacokinetics of subcutaneous administration of insulin aspart is presented below.

#### Absorption and Bioavailability

In studies in healthy volunteers (total n=107) and patients with type 1 diabetes (total


n=40), the median time to maximum concentration of insulin aspart in these trials was 40 to 50 minutes versus 80 to 120 minutes, for regular human insulin respectively.

The relative bioavailability of insulin aspart (0.15 units/kg) compared to regular human insulin indicates that the two insulins are absorbed to a similar extent.

In a clinical trial in patients with type 1 diabetes, insulin aspart and regular human insulin, both administered subcutaneously at a dose of 0.15 units/kg body weight, reached mean maximum concentrations of 82 and 36 mU/L, respectively.

### Distribution

Insulin aspart has a low binding affinity to plasma proteins (<10%), similar to that seen with regular human insulin.



**Figure 2. Serial mean serum free insulin concentration collected up to 6 hours following a single 0.15 units/kg pre-meal dose of insulin aspart (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 diabetes.**

### Metabolism and Elimination

After subcutaneous administration in normal male volunteers (n=24), insulin aspart was eliminated with an average apparent half-life of 81 minutes.

### Specific Populations

*Pediatric Patients:* The pharmacokinetic and pharmacodynamic properties of insulin aspart and regular human insulin were evaluated in a single dose study in 18 pediatric patients with type 1 diabetes in 2 age groups: 6-12 years, n=9 and 13-17 years (Tanner grade  $\geq 2$ ), n=9. The relative differences in pharmacokinetics and pharmacodynamics in the pediatric patients with type 1 diabetes in both age groups between insulin aspart and regular human insulin were similar to those in healthy adult subjects and adults with type 1 diabetes.

*Geriatric Patients:* The pharmacokinetic and pharmacodynamic properties of insulin aspart and regular human insulin were investigated in a single dose study in 18 subjects

with type 2 diabetes who were  $\geq 65$  years of age. The relative differences in pharmacokinetics and pharmacodynamics in geriatric patients with type 2 diabetes between insulin aspart and regular human insulin were similar to those in younger adults.

*Male and Female Patients:* In healthy volunteers given a single subcutaneous dose of insulin aspart 0.06 units/kg, no difference in insulin aspart levels was seen between males and females based on comparison of  $AUC_{(0-10h)}$  or  $C_{max}$ .

*Obese Patients:* A single subcutaneous dose of 0.1 units/kg insulin aspart was administered in a study of 23 patients with type 1 diabetes and a wide range of body mass index (BMI, 22–39 kg/m<sup>2</sup>). The pharmacokinetic parameters, AUC and  $C_{max}$ , of insulin aspart were generally unaffected by BMI in the different groups – BMI 19–23 kg/m<sup>2</sup> (n=4); BMI 23–27 kg/m<sup>2</sup> (n=7); BMI 27–32 kg/m<sup>2</sup> (n=6) and BMI >32 kg/m<sup>2</sup> (n=6). Clearance of insulin aspart was reduced by 28% in patients with BMI >32 kg/m<sup>2</sup> compared to patients with BMI <23 kg/m<sup>2</sup>.

*Patients with Renal Impairment:* A single subcutaneous dose of 0.08 units/kg insulin aspart was administered in a study to subjects with either normal renal function (n=6) creatinine clearance (CLcr) (>80 ml/min) or mild (n=7; CLcr=50–80 ml/min), moderate (n=3; CLcr=30–50 ml/min) or severe (but not requiring hemodialysis) (n=2; CLcr = <30 ml/min) renal impairment. In this study, there was no apparent effect of creatinine clearance values on AUC and  $C_{max}$  of insulin aspart.

*Patients with Hepatic Impairment:* A single subcutaneous dose of 0.06 units/kg insulin aspart was administered in an open-label, single-dose study of 24 subjects (n=6/group) with different degree of hepatic impairment (mild, moderate and severe) having Child-Pugh Scores ranging from 0 (healthy volunteers) to 12 (severe hepatic impairment). In this study, there was no correlation between the degree of hepatic impairment and any insulin aspart pharmacokinetic parameter.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of insulin aspart products. In 52-week studies, Sprague-Dawley rats were dosed subcutaneously with insulin aspart at 10, 50, and 200 units/kg/day (approximately 2, 8, and 32 times the human subcutaneous dose of 1.0 units/kg/day, based on units/body surface area, respectively). At a dose of 200 units/kg/day, insulin aspart increased the incidence of mammary gland tumors in females when compared to untreated controls. The relevance of these findings to humans is unknown.

Insulin aspart was not genotoxic in the following tests: Ames test, mouse lymphoma cell forward gene mutation test, human peripheral blood lymphocyte chromosome aberration test, *in vivo* micronucleus test in mice, and in *ex vivo* UDS test in rat liver hepatocytes.

In fertility studies in male and female rats, at subcutaneous doses up to 200 units/kg/day (approximately 32 times the human subcutaneous dose, based on units/body surface area), no direct adverse effects on male and female fertility, or

general reproductive performance of animals was observed.

### 13.2 Animal Toxicology and/or Pharmacology

In standard biological assays in mice and rabbits, one unit of insulin aspart has the same glucose-lowering effect as one unit of regular human insulin.

## 14 CLINICAL STUDIES

### 14.1 Overview of Clinical Studies

The safety and effectiveness of subcutaneous insulin aspart were compared to regular human insulin in 596 type 1 diabetes adult, 187 pediatric type 1 diabetes, and 91 adult type 2 diabetes patients using NPH as basal insulin (see Tables 3, 4, 5). The reduction in glycated hemoglobin (HbA<sub>1c</sub>) was similar to regular human insulin.

### 14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections

#### Type 1 Diabetes - Adults (see Table 3)

Two 24-week, open-label, active-controlled studies were conducted to compare the safety and efficacy of insulin aspart to regular human insulin injection in adult patients with type 1 diabetes. Because the two study designs and results were similar, data are shown for only one study (see Table 3).

The mean age of the trial population was 39 years and mean duration of diabetes was 15.7 years. Fifty-one percent were male. Ninety-four percent were Caucasian, 2% were Black and 4% were Other. The mean BMI was approximately 25.6 kg/m<sup>2</sup>.

Insulin aspart was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA<sub>1c</sub> were comparable for the two treatment regimens in this study (Table 3).

**Table 3. Type 1 Diabetes Mellitus - Adult (insulin aspart plus NPH insulin vs. regular human insulin plus NPH insulin)**

	<b>Insulin aspart + NPH (n=596)</b>	<b>Regular Human Insulin + NPH (n=286)</b>
Baseline HbA <sub>1c</sub> (%)*	7.9 ± 1.1	8.0 ± 1.2
Change from Baseline HbA <sub>1c</sub> (%)	-0.1 ± 0.8	0.0 ± 0.8
Treatment Difference in HbA <sub>1c</sub> , Mean (95% confidence interval)	-0.2 (-0.3, -0.1)	

\* Values are Mean ± SD



## Type 1 Diabetes - Pediatric (see Table 4)

The efficacy of insulin aspart to improve glycemic control in pediatric patients with type 1 diabetes mellitus is based on an adequate and well-controlled trial of regular human insulin in pediatric patients with type 1 diabetes mellitus (Table 4). This 24-week, parallel-group study of pediatric patients with type 1 diabetes (n=283), aged 6 to 18 years, compared two subcutaneous multiple-dose treatment regimens: insulin aspart (n=187) or regular human insulin (n=96). NPH insulin was administered as the basal insulin. Similar effects on HbA<sub>1c</sub> were observed in both treatment groups (Table 4).

Subcutaneous administration of insulin aspart and regular human insulin have also been compared in pediatric patients with type 1 diabetes (n=26) aged 2 to 6 years with similar effects on HbA<sub>1c</sub>.

**Table 4. Pediatric Subcutaneous Administration of Insulin Aspart in Type 1 Diabetes (24 weeks; n=283)**

	<b>Insulin aspart + NPH (n=187)</b>	<b>Regular Human Insulin + NPH (n=96)</b>
Baseline HbA <sub>1c</sub> (%)*	8.3 ± 1.2	8.3 ± 1.3
Change from Baseline HbA <sub>1c</sub> (%)	0.1 ± 1.0	0.1 ± 1.1
Treatment Difference in HbA <sub>1c</sub> , Mean (95% confidence interval)	-0.2 (-0.5, 0.1)	

\* Values are Mean ± SD

## **14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections**

### Type 2 Diabetes - Adults (see Table 5)

One six-month, open-label, active-controlled study was conducted to compare the safety and efficacy of insulin aspart to regular human insulin in patients with type 2 diabetes (Table 5).

The mean age of the trial population was 56.6 years and mean duration of diabetes was 12.7 years. Sixty-three percent were male. Seventy-six percent were Caucasian, 9% were Black and 15% were Other. The mean BMI was approximately 29.7 kg/m<sup>2</sup>.

Insulin aspart was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA<sub>1c</sub> were comparable for the two treatment regimens.

**Table 5. Subcutaneous Insulin Aspart Administration in Type 2 Diabetes (6 months; n=176)**

	<b>Insulin aspart + NPH (n=90)</b>	<b>Regular Human Insulin + NPH (n=86)</b>
--	--	---

Baseline HbA <sub>1c</sub> (%)*	8.1 ± 1.2	7.8 ± 1.1
Change from Baseline HbA <sub>1c</sub> (%)	-0.3 ± 1.0	-0.1 ± 0.8
Treatment Difference in HbA <sub>1c</sub> , Mean (95% confidence interval)	-0.1 (-0.4, 0.1)	

\* Values are Mean ± SD

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### 16.1 How Supplied

MERILOG (insulin aspart-szjj) injection 100 units/mL (U-100) is available as a clear and colorless solution in:

Dosage Unit	NDC #
One 10 mL multiple-dose vial per carton	NDC 0024-5927-00
Five 3 mL single-patient-use SoloStar prefilled pens per carton	NDC 0024-5928-05

The MERILOG SoloStar prefilled pen dials in 1-unit increments.

Needles are not included in MERILOG SoloStar packs. Only use needles that are compatible for use with MERILOG SoloStar which are sold separately, including needles from Becton, Dickinson and company (BD) (such as BD Ultra-Fine<sup>®</sup>), Ypsomed (such as Clickfine<sup>®</sup>), and Owen Mumford (such as Unifine<sup>®</sup> Pentips<sup>®</sup>).

### 16.2 Recommended Storage

Dispense in the original sealed carton with the enclosed Instructions for Use.

Store unused MERILOG in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze MERILOG and do not use MERILOG if it has been frozen. Do not expose MERILOG to excessive heat or light.

Do **not** withdraw MERILOG into a syringe and store for later use.

Always remove and discard the needle after each injection from the MERILOG SoloStar prefilled pen and store without a needle attached.

The storage conditions are summarized in the following table:

**Table 6. Storage Conditions for Vial and SoloStar Prefilled Pen**

MERILOG presentation	Not in-use (unopened) Room Temperature	Not in-use (unopened) Refrigerated (2°C to 8°C)	In-use (opened) Room Temperature

Presentation	(up to 30°C [86°F])	(2°C to 8°C [36°F to 46°F])	(up to 30°C [86°F])
10 mL multiple-dose vial	28 days	Until expiration date	28 days (refrigerated/room temperature)
3 mL single-patient-use SoloStar prefilled pen	28 days	Until expiration date	28 days (Do not refrigerate)

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

### Never Share a MERILOG SoloStar Prefilled Pen between Patients

Advise patients that they must never share MERILOG SoloStar prefilled pen device with another person even if the needle is changed, because doing so carries a risk for transmission of blood-borne pathogens. Advise patients using MERILOG vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens [see *Warnings and Precautions (5.1)*].

### Hyperglycemia or Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of MERILOG therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia [see *Warnings and Precautions (5.3)*].

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery.

Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see *Warnings and Precautions (5.2)*].

### Hypoglycemia with Medication Errors

Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products [see *Warnings and Precautions (5.4)*].

### Hypersensitivity Reactions

Advise patients that hypersensitivity reactions have occurred with insulin aspart products. Inform patients of the symptoms of hypersensitivity reactions [see *Warnings and Precautions (5.5)*].

Manufactured by:

sanofi-aventis U.S. LLC  
Bridgewater, NJ 08807  
A SANOFI COMPANY  
U.S. License No. 1752

©2025 Sanofi. All rights reserved.

All trademarks mentioned in this document are the property of the Sanofi group with the exception of Novolog, BD Ultra-Fine, Clickfine, Unifine, and Pentips.

**PATIENT INFORMATION**  
**MERILOG™ [mer-ih-lawg]**  
**(insulin aspart-szjj)**  
**injection, for subcutaneous use**  
**100 units/mL (U-100)**

**Do not share your MERILOG SoloStar prefilled pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.**

**What is MERILOG?**

- MERILOG is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

**Who should not take MERILOG?**

**Do not take MERILOG if you:**

- are having an episode of low blood sugar (hypoglycemia).
- have an allergy to insulin aspart products or any of the ingredients in MERILOG.

**Before taking MERILOG, tell your healthcare provider about all your medical conditions including, if you are:**

- pregnant, planning to become pregnant, or are breastfeeding.
- taking new prescription or over-the-counter medicines, vitamins, or herbal supplements.

**Before you start taking MERILOG, talk to your healthcare provider about low blood sugar and how to manage it.**

**How should I take MERILOG?**

- **Read the Instructions for Use** that come with your MERILOG.
- Take MERILOG exactly as your healthcare provider tells you to.
- **MERILOG starts acting fast.** You should eat a meal within 5 to 10 minutes after you take your dose of MERILOG.
- Know the type and strength of insulin you take. **Do not** change the type of insulin you take unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take different types of insulin.
- **Check your blood sugar levels.** Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels.
- **Do not reuse or share your needles with other people.** You may give other people a serious infection or get a serious infection from them.
- MERILOG can be injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs (thighs), or upper arms.

- **Change (rotate) your injection sites within the area you choose with each dose** to reduce your risk of getting pits in skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites.
  - **Do not** use the exact same spot for each injection.
  - **Do not** inject where the skin has pits, is thickened, or has lumps.
  - **Do not** inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

### **What should I avoid while taking MERILOG?**

#### **While taking MERILOG do not:**

- Drive or operate heavy machinery, until you know how MERILOG affects you.
- Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.

### **What are the possible side effects of MERILOG?**

#### **MERILOG can cause serious side effects that can lead to death, including:**

**Low blood sugar (hypoglycemia).** Signs and symptoms that may indicate low blood sugar include:

- dizziness or light-headedness
- sweating
- confusion
- fast heart beat
- blurred vision
- slurred speech
- shakiness
- anxiety, irritability, or mood changes
- hunger
- headache

#### **Your insulin dose may need to change because of:**

- change in level of physical activity or exercise
- weight gain or loss
- increased stress
- illness
- change in diet

#### **Other common side effects of MERILOG may include:**

- low potassium in your blood (hypokalemia), reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.

#### **Get emergency medical help if you have:**

- trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

These are not all the possible side effects of MERILOG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### **General information about the safe and effective use of MERILOG.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about MERILOG that is written for health professionals. Do not use MERILOG for a condition for which it was not prescribed. Do not give MERILOG to other people, even if they have the same symptoms that you have. It may harm them.

### **What are the ingredients in MERILOG?**

**Active Ingredient:** insulin aspart-szjj

**Inactive Ingredients:** metacresol, phenol, polysorbate 20, sodium chloride, zinc

chloride and Water for Injection, USP. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH.

**Manufactured by:** sanofi-aventis U.S. LLC, Bridgewater, NJ 08807, A SANOFI COMPANY. U.S. License No. 1752

For more information, go to [www.sanofi.com](http://www.sanofi.com) or call 1-800-633-1610.

©2025 Sanofi. All rights reserved.

*All trademarks mentioned in this document are the property of the Sanofi group.*

This Patient Information has been approved by the U.S. Food and Drug Administration.

**Issued: February 2025**

## **INSTRUCTIONS FOR USE**

### **MERILOG™ [mer-ih-lawg]**

**(insulin aspart-szjj)**

**injection, for subcutaneous use**

**10 mL multiple-dose vial: 100 units/mL (U-100)**

This Instructions for Use contains information on how to inject MERILOG.

Read this Instructions for Use before you start taking MERILOG and each time you get a new MERILOG vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

**Do not share your MERILOG syringes with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.**

### **Supplies needed to give your injection**

- a MERILOG 10 mL vial
- a U-100 insulin syringe and needle
- 2 alcohol swabs
- 1 sharps container for throwing away used needles and syringes. See "**Disposing of used needles and syringes**" at the end of these instructions.

### **Preparing your MERILOG dose**

- Wash your hands with soap and water or with alcohol.
- Check the MERILOG label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
- Check that the insulin is clear and colorless. **Do not** use the vial if the insulin looks cloudy, colored or contains particles.
- **Do not** use MERILOG after the expiration date stamped on the label or 28 days after you first use it.
- **Always use a syringe that is marked for U-100 insulin.** If you use a syringe other than a U-100 insulin syringe, you may get the wrong dose of insulin.
- **Always use a new syringe or needle for each injection to help maintain sterility and prevent blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.**

**Need help?**

If you have any questions about your vial or about diabetes, ask your healthcare provider, or call sanofi-aventis at 1-800-633-1610.

**Step 1:**

If you are using a new vial, remove the protective cap. **Do not** remove the stopper (see **Figure A**).



(**Figure A**)

**Step 2:**


Wipe the top of the vial with an alcohol swab. You do not have to shake the vial of MERILOG before use (see **Figure B**).




(**Figure B**)

**Step 3:**

Draw air into the syringe equal to your insulin dose (see **Figure C**). Put the needle through the rubber top of the vial and push the plunger to inject the air into the vial (see **Figure D**).




(Figure C)



(Figure D)

#### Step 4:

Leave the syringe in the vial and turn both upside down. Hold the syringe and vial firmly in one hand. Make sure the tip of the needle is in the insulin. With your free hand, pull the plunger to withdraw the correct dose into the syringe (see **Figure E**).




(Figure E)

#### Step 5:

Before you take the needle out of the vial, check the syringe for air bubbles. If bubbles are in the syringe, hold the syringe straight up and tap the side of the syringe until the bubbles float to the top. Push the bubbles out with the plunger and draw insulin back in until you have the correct dose (see **Figure F**).





(Figure F)

### Step 6:


Remove the needle from the vial. Do not let the needle touch anything. You are now ready to inject.

### Giving your MERILOG injection with a syringe

- Inject your insulin exactly as your healthcare provider has shown you.
- **MERILOG starts acting fast. You should eat a meal within 5 to 10 minutes after you take your dose of MERILOG.**


### Step 7:

- Choose your injection site: MERILOG is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs (thighs) or upper arms (see **Figure G**).
- **Do not** use the exact same spot for each injection. **Change (rotate) your injection sites within the area you choose for each dose** to reduce your risk of getting pits in the skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites.
- **Do not** inject where the skin has pits, is thickened, or has lumps.
- **Do not** inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.



(Figure G)


- Wipe the skin with an alcohol swab to clean the injection site. Let the injection site dry before you inject your dose (see **Figure H**).



(Figure H)

**Step 8:**

- Pinch the skin.
- Insert the needle in the way your healthcare provider showed you.
- Release the skin.
- Slowly push in the plunger of the syringe all the way, making sure you have injected all the insulin.
- Leave the needle in the skin for about **10** seconds (see **Figure I**).



(Figure I)

**Step 9:**

- Pull the needle straight out of your skin.
- Gently press the injection site for several seconds. **Do not** rub the area.
- **Do not** recap the used needle. Recapping the needle can lead to a needle-stick injury.

**Disposing of used needles and syringes**

- Put your used needles and syringes in a FDA-cleared sharps disposal container right

away after use. **Do not** throw away (dispose of) loose needles and syringes in your household trash.

- If you do not have a FDA-cleared sharps container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak resistant, and
  - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: <http://www.fda.gov/safesharpsdisposal>.
- **Do not** dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. **Do not** recycle your used sharps disposal container.

## **How should I store MERILOG?**

### **Unopened (not in-use) MERILOG vials**

- Store unused MERILOG vials in the refrigerator between 36°F to 46°F (2°C to 8°C).
- **Do not** freeze MERILOG.
- Keep MERILOG away from direct heat and light.
- If a vial has been frozen or overheated, throw it away.
- Unopened vials can be used until the expiration date on the carton and label if they have been stored in the refrigerator.
- Unopened vials should be thrown away after 28 days if they are stored at room temperature.

### **After MERILOG vials have been opened (in-use)**

- Store in-use (opened) MERILOG vials in a refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature below 86°F (30°C) for up to **28 days**.
- **Do not** freeze MERILOG.
- Do not expose MERILOG to excessive heat or light.
- If a vial has been frozen, throw it away.
- The MERILOG vial you are using should be thrown away after **28** days, even if it still has insulin left in it.

Manufactured by:  
sanofi-aventis U.S. LLC  
Bridgewater, NJ 08807  
A SANOFI COMPANY  
U.S. License No. 1752

©2025 Sanofi. All rights reserved.

All trademarks mentioned in this document are the property of the Sanofi group.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

**Approved: February 2025**

## **INSTRUCTIONS FOR USE**

**MERILOG™ SoloStar® [mer-ih-lawg soh-loh-stahr]**

**(insulin aspart-szjj)**

**injection, for subcutaneous use**

**3 mL single-patient-use prefilled pen: 100 units/mL (U-100)**

This Instructions for Use contains information on how to inject MERILOG.

Read this Instructions for Use before you start taking MERILOG and each time you get a new MERILOG SoloStar prefilled pen. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

**Do not share your MERILOG SoloStar prefilled pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.**

People who are blind or have vision problems should not use MERILOG SoloStar prefilled pen without help from a person trained to use MERILOG SoloStar prefilled pen.

**MERILOG SoloStar is a disposable prefilled pen used to inject MERILOG. Each MERILOG SoloStar has 300 units of insulin which can be used for multiple injections. You can select doses from 1 to 80 units in steps of 1 unit. The pen plunger moves with each dose. The plunger will only move to the end of the cartridge when 300 units of insulin have been given.**

### **Important information**

- **Do not** use your pen if it is damaged or if you are not sure that it is working properly.
- **Do not** use a syringe to remove insulin from your pen.
- **Do not reuse needles.** If you do, you might get the wrong dose of MERILOG or increase the chance of getting an infection.
- Always perform a safety test (see **Step 3**).
- Always carry a spare pen and spare needles in case they are lost or stop working.
- Change (rotate) your injection sites within the area you choose for each dose (see "**Places to inject**").

### **Learn to inject**

- Talk with your healthcare provider about how to inject before using your pen.
- Ask for help if you have problems handling the pen.
- Read all of these instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin.

### **Need help?**

If you have any questions about your pen or about diabetes, ask your healthcare provider, or call sanofi-aventis at **1-800-633-1610**.


### **Extra items you will need:**

- a new sterile needle (see **Step 2**).

- an alcohol swab.
- a puncture-resistant container for used needles and pens. (See "**Throwing your pen away**".)


### Places to inject

- Inject your insulin exactly as your healthcare provider has shown you.
- Inject your insulin under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs (thighs) or upper arms (see **Figure A**).
- Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting pits in skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites.
- **Do not** inject where the skin has pits, is thickened, or has lumps.
- **Do not** inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.



(Figure A)

### Get to know your pen



\*You will not see the plunger until you have injected a few doses

(Figure B)

### Step 1: Check your pen

Take a new pen out of the refrigerator at least **1** hour before you inject. Cold insulin is more painful to inject.


**1A Check the name and expiration date on the label of your pen.**

- Make sure you have the correct insulin (see **Figure C**).
- **Do not** use your pen after the expiration date.



(Figure C)


**1B Pull off the pen cap (see Figure D).**



(Figure D)


**1C Check that the insulin is clear and colorless (see Figure E).**

- **Do not** use the pen if the insulin looks cloudy, colored or contains particles.



(Figure E)

**1D Wipe the rubber seal with an alcohol swab (see Figure F).**



**(Figure F)**

**If you have other injector pens:**

- Making sure you have the correct medicine is especially important if you have other injector pens.

**Step 2: Attach a new needle**


- **Do not** reuse needles. Always use a new sterile needle for each injection. This helps stop blocked needles, contamination, and infection.
- Only use needles\* that are compatible for use with MERILOG SoloStar which are sold separately, including needles from Becton, Dickinson and company (BD) (such as BD Ultra-Fine<sup>®</sup>), Ypsomed (such as Clickfine<sup>®</sup>), and Owen Mumford (such as Unifine<sup>®</sup> Pentips<sup>®</sup>).

**2A Take a new needle and peel off the protective seal (see Figure G).**




**(Figure G)**

**2B Keep the needle straight and screw it onto the pen until fixed. Do not over-tighten (see Figure H).**



(Figure H)

**2C Pull off the outer needle cap. Keep this for later (see Figure I).**



(Figure I)

**2D Pull off the inner needle cap and throw away (see Figure J).**



(Figure J)

**Handling needles:**

- Take care when handling needles to prevent accidental needle-stick injury. You may give other people a serious infection, or get a serious infection from them (cross-infection).

**Step 3: Do a safety test**


**Always do a safety test before each injection to:**



- Check your pen and the needle to make sure they are working properly.
- Make sure that you get the correct insulin dose.

You must perform safety tests before you use the pen until you see insulin coming out of the needle tip. If you see insulin coming out of the needle tip, the pen is ready to use. If you do not see insulin coming out before taking your dose, you could get an underdose or no insulin at all. This could cause high blood sugar.


**3A Select 2 units by turning the dose selector until the dose pointer is at the 2 mark (see Figure K).**



(Figure K)

**3B Press the injection button all the way in (see Figure L).**

- When insulin comes out of the needle tip, your pen is working correctly.



(Figure L)

**If no insulin appears:**

- You may need to repeat this step up to 3 times before seeing insulin.
- If no insulin comes out after the third time, the needle may be blocked. If this happens:

- change the needle (see **Step 6** and **Step 2**),
  - then repeat the safety test (**Step 3**).
- **Do not** use your pen if there is still no insulin coming out of the needle tip. Use a new pen.
  - **Do not** use a syringe to remove insulin from your pen.

**If you see air bubbles:**

- You may see air bubbles in the insulin. This is normal, they will not harm you.

**Step 4: Select the dose**

**Do not** select a dose or press the injection button without a needle attached. This may damage your pen.

**4A Make sure a needle is attached and the dose is set to "0"** (see **Figure M**).



(Figure M)

**4B Turn the dose selector until the dose pointer lines up with your dose** (see **Figure N**).

- Always check the number in the dose window to make sure you dialed the correct dose.
- If you turn past your dose, you can turn back down.
- If there are not enough units left in your pen for your dose, the dose selector will stop at the number of units left.
- If you cannot select your full prescribed dose, use a new pen or inject the remaining units and use a new pen to complete your dose. If you use a new pen, perform a safety test (see **Step 3**).



(Figure N)

### How to read the dose window

Even numbers are shown in line with dose pointer (see **Figure O**).



**20 units selected**  
(Figure O)

Odd numbers are shown as a line between even numbers (see **Figure P**).



**21 units selected**  
(Figure P)

### Units of insulin in your pen:

- Your pen contains a total of **300** units of insulin. You can select doses from **1** to **80**

units in steps of **1** unit. Each pen contains more than 1 dose.

- You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.


### Step 5: Inject your dose

If you find it hard to press the injection button in, **do not** force it as this may break your pen. See the section after **Step 5E** below for help.

**5A Choose a place to inject as shown in the picture labeled "Places to inject"** (see **Figure A**). **Wipe the skin with an alcohol swab to clean the injection site. Let the injection site dry before you inject your dose.**

**5B Push the needle into your skin as shown by your healthcare provider** (see **Figure Q**).


- **Do not** touch the injection button yet.



(Figure Q)

**5C Place your thumb on the injection button. Then press all the way in and hold** (see **Figure R**).


- **Do not** press at an angle. Your thumb could block the dose selector from turning.



(Figure R)

**5D Keep the injection button held in and when you see "0" in the dose window, slowly count to 10** (see **Figure S**).

- This will make sure you get your full dose.



(Figure S)

**5E After holding and slowly counting to 10, release the injection button. Then remove the needle from your skin.**

**If you find it hard to press the button in:**


- Change the needle (see **Step 6** and **Step 2**) then do a safety test (see **Step 3**).
- If you still find it hard to press in, get a new pen.
- **Do not** use a syringe to remove insulin from your pen.

**Step 6: Remove the needle**

- Take care when handling needles to prevent needle-stick injury and cross-infection.
- **Do not** put the inner needle cap back on.

**6A Grip the widest part of the outer needle cap. Keep the needle straight and guide it into the outer needle cap. Then push firmly on** (see **Figure T**).


- The needle can puncture the cap if it is recapped at an angle.



(Figure T)

**6B Grip and squeeze the widest part of the outer needle cap. Turn your pen several times with your other hand to remove the needle** (see **Figure U**).

- Try again if the needle does not come off the first time.



(Figure U)


**6C Throw away the used needle in a puncture-resistant container** (see **Figure V**) (see "Throwing your pen away" at the end of this Instructions for Use).



(Figure V)

**6D Put your pen cap back on** (see **Figure W**).

- Do not put the pen back in the refrigerator.



(Figure W)

## How to store your pen

### Before first use

- Keep new pens in the refrigerator between **36°F to 46°F (2°C to 8°C)**.

- **Do not** freeze. **Do not** use MERILOG if it has been frozen.

### **After first use**

- Keep your pen at room temperature below **86°F (30°C)**.
- **Do not** expose MERILOG to excessive heat or light.
- Store your pen with the pen cap on.
- **Do not** put your pen back in the refrigerator.
- **Do not** store your pen with the needle attached.
- **Keep MERILOG SoloStar pens and needles out of the reach of children.**
- Only use your pen for **up to 28 days** after its first use. Throw away the MERILOG SoloStar pen you are using after 28 days, even if it still has insulin left in it.

### **How to care for your pen**

#### **Handle your pen with care**

- **Do not** drop your pen or knock it against hard surfaces.
- If you think that your pen may be damaged, **do not** try to fix it. Use a new one.

#### **Protect your pen from dust and dirt**

- You can clean the outside of your pen by wiping it with a damp cloth (water only). **Do not** soak, wash or lubricate your pen. This may damage it.

#### **Throwing your pen away**

- The used MERILOG SoloStar pen may be thrown away in your household trash after you have removed the needle.
- Put the used needles in a FDA-cleared sharps disposal container right away after use. **Do not** throw away (dispose of) loose needles in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak-resistant, and
  - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: <http://www.fda.gov/safesharpsdisposal>.
- **Do not** dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. **Do not** recycle your used sharps disposal container.

Manufactured by:  
sanofi-aventis U.S. LLC  
Bridgewater, NJ 08807  
A SANOFI COMPANY  
U.S. License No. 1752

©2025 Sanofi. All rights reserved.

All trademarks mentioned in this document are the property of the Sanofi group with the exception of BD Ultra-Fine, Clickfine, Unifine, and Pentips.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

**Approved: February 2025**

**PRINCIPAL DISPLAY PANEL - 10 mL Vial Label**

NDC 0024-5927-00

Rx only

Merilog™

(insulin aspart-szjj) injection

100 units/mL (U-100)

For subcutaneous injection only


Dosage: See Prescribing Information

10 mL multiple-dose vial

Mfd by: sanofi-aventis U.S. LLC

U.S. Lic. No. 1752

<MAT>930716



**PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton**

NDC 0024-5927-00

Rx only



Merilog™

(insulin aspart-szjj) injection

100 units/mL (U-100)

For subcutaneous injection only

Use only with a U-100 syringe

One 10 mL multiple-dose vial

sanofi



**PRINCIPAL DISPLAY PANEL - 3 mL Pen Label**

NDC 0024-5928-00

3 mL Prefilled Pen

Rx only

Merilog™ SoloStar®

(insulin aspart-szjj) injection

For Single Patient Use Only

100 units/mL (U-100)

For subcutaneous injection only

Dosage: See Prescribing Information

Mfd by: sanofi-aventis U.S. LLC. U.S. Lic. No. 1752

<MAT>  
930557



Lot :  
EXP :

NDC 0024-5928-00



3 mL Prefilled Pen Rx only

**Merilog™ SoloStar®**  
*(insulin aspart-szjj) injection*

**For Single Patient Use Only**

**100 units/mL (U-100)**  
For subcutaneous injection only

**Dosage:** See Prescribing Information  
Mfd by: sanofi-aventis U.S. LLC. U.S. Lic. No. 1752

**PRINCIPAL DISPLAY PANEL - 3 mL Pen Carton**

Rx only

NDC 0024-5928-05

Merilog™ SoloStar®  
(insulin aspart-szjj) injection

For Single Patient Use Only

100 units/mL (U-100)

For subcutaneous injection only

Do not mix with other insulins

Needles not included

Dispense in this sealed carton

Five 3 mL Prefilled Pens

sanofi



## MERILOG

insulin aspart-szjj injection, solution

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0024-5927
<b>Route of Administration</b>	SUBCUTANEOUS, INTRAVENOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
INSULIN ASPART (UNII: D933668QVX) (INSULIN ASPART - UNII:D933668QVX)	INSULIN ASPART	100 [iU] in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>METACRESOL</b> (UNII: GGO4Y809LO)	1.72 mg in 1 mL
<b>PHENOL</b> (UNII: 339NCG44TV)	1.5 mg in 1 mL
<b>POLYSORBATE 20</b> (UNII: 7T1F30V5YH)	0.02 mg in 1 mL
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	6.8 mg in 1 mL
<b>ZINC CHLORIDE</b> (UNII: 86Q357L16B)	0.04 mg in 1 mL
<b>WATER</b> (UNII: 059QF0KO0R)	

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0024-5927-00	1 in 1 CARTON	02/14/2025	
1		10 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA761325	02/14/2025	

MERILOG			
insulin aspart-szjj injection, solution			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0024-5928
Route of Administration	SUBCUTANEOUS, INTRAVENOUS		
Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
<b>INSULIN ASPART</b> (UNII: D933668QVX) (INSULIN ASPART - UNII:D933668QVX)	INSULIN ASPART	100 [iU] in 1 mL	
Inactive Ingredients			
Ingredient Name	Strength		
<b>METACRESOL</b> (UNII: GGO4Y809LO)	1.72 mg in 1 mL		
<b>PHENOL</b> (UNII: 339NCG44TV)	1.5 mg in 1 mL		
<b>POLYSORBATE 20</b> (UNII: 7T1F30V5YH)	0.02 mg in 1 mL		
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	6.8 mg in 1 mL		
<b>ZINC CHLORIDE</b> (UNII: 86Q357L16B)	0.04 mg in 1 mL		
<b>WATER</b> (UNII: 059QF0KO0R)			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0024-5928-05	5 in 1 BOX	02/14/2025	
1	NDC:0024-5928-00	3 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA761325	02/14/2025	

**Labeler** - Sanofi-Aventis U.S. LLC (824676584)

**Registrant** - Sanofi-Aventis Deutschland GmbH (313218430)

## Establishment

Name	Address	ID/FEI	Business Operations
Sanofi-Aventis Deutschland GmbH		313218430	MANUFACTURE(0024-5927, 0024-5928) , API MANUFACTURE(0024-5927, 0024-5928) , PACK(0024-5927, 0024-5928) , LABEL(0024-5927, 0024-5928)

Revised: 2/2025

Sanofi-Aventis U.S. LLC